INDV (Indivior Pharmaceuticals) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INDV Indivior Pharmaceuticals Inc INDV
78 GF Score
Price $35.53
GF Value $24.67
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Indivior Pharmaceuticals  (NAS:INDV) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Indivior Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms


Indivior Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Indivior Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Indivior Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Indivior Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

INDV vs AMLX, RGC, SUPN: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Indivior Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indivior Pharmaceuticals Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Indivior Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Indivior Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


INDV
78GF Score
Indivior Pharmaceuticals Inc INDV
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indivior Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Indivior Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Indivior Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-1.763/333.9520*333.9520
=-1.763

Current CPI (Jun. 2026) = 333.9520.

Indivior Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 -2.651 241.428 -3.667
201612 -2.047 241.432 -2.831
201703 -1.464 243.801 -2.005
201706 -0.922 244.955 -1.257
201709 -0.513 246.819 -0.694
201712 -1.407 246.524 -1.906
201803 -0.694 249.554 -0.929
201806 -0.295 251.989 -0.391
201809 0.330 252.439 0.437
201812 0.453 251.233 0.602
201903 0.911 254.202 1.197
201906 1.404 256.143 1.830
201909 1.724 256.759 2.242
201912 1.430 256.974 1.858
202003 0.266 258.115 0.344
202006 0.396 257.797 0.513
202009 0.545 260.280 0.699
202012 0.559 260.474 0.717
202103 1.116 264.877 1.407
202106 1.585 271.696 1.948
202109 1.113 274.310 1.355
202112 1.445 278.802 1.731
202203 1.643 287.504 1.908
202206 1.647 296.311 1.856
202209 1.648 296.808 1.854
202212 0.374 296.797 0.421
202303 0.522 301.836 0.578
202306 0.849 305.109 0.929
202309 -0.174 307.789 -0.189
202312 0.000 306.746 0.000
202403 0.074 312.332 0.079
202406 -0.903 314.175 -0.960
202409 -1.289 315.301 -1.365
202412 -2.696 315.605 -2.853
202503 -2.280 319.799 -2.381
202506 -2.056 322.561 -2.129
202509 -1.656 324.800 -1.703
202512 -0.784 324.054 -0.808
202603 -1.180 330.213 -1.193
202606 -1.763 333.952 -1.763

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of $35.53 is trading 44% above its estimated GF Value™ of $24.67. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INDV:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $24.67 vs. price of $35.53 (44% above fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Indivior Pharmaceuticals Business Description

Other Exchanges E7P:Germany
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
78GF Score

Get the complete analysis for INDV

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.53
Price
$24.67
GF Value